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Summary
Background: Contrast-induced nephropathy (CIN) is known to increase morbidity and
mortality of cardiovascular disease. Recent studies have shown statins prevented CIN
after contrast media exposure, but optimal statin type and dosage are still unknown.
Purpose: The aims of the present study were to evaluate whether chronic pravas-
tatin treatment before scheduled coronary angiography or percutaneous coronary
intervention could reduce the incidence of CIN and to elucidate the factors related
to CIN in patients with renal insufﬁciency.
Methods: We studied 431 consecutive patients with renal insufﬁciency. One hun-
dred ninety-four patients were receiving pravastatin treatment as standard chronic
treatment of hypercholesterolemia. Serum creatinine levels were measured at
baseline (pre-procedure) and within 48 h after contrast media exposure (peak post-
procedure). CIN was deﬁned as an increase in the serum creatinine values of ≥25%
or ≥0.5mg/dl after contrast media exposure. Logistic regression analysis was per-
formed to evaluate the important factors related to CIN using four variables: age,
pravastatin, pre-procedure serum creatinine, and contrast volume.
Results: CIN was observed in 36 patients (8.4%). Patients without pravastatin
(p < 0.01), high level pre-procedure serum creatinine (p < 0.01), and high con-
trast volume (p = 0.034) had a signiﬁcantly higher incidence of CIN. Logistic
regression analysis revealed that pravastatin treatment (2 = 6.549, p = 0.011,
odds ratio = 0.34), pre-procedure serum creatinine (2 = 6.294, p = 0.009, odds
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ratio = 2.78), and contrast volume (2 = 4.484, p = 0.034, odds ratio = 1.01) were inde-
pendently related to the decreased risk of CIN.
Conclusions: Chronic pravastatin treatment before contrast media exposure was
important for preventing CIN in patients with renal insufﬁciency. Also, reducing the
dose of contrast media was important for preventing CIN in patients with high-baseline
serum creatinine levels.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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The exclusion criteria were as follows: (1)
baseline pre-procedure serum creatinine level© 2009 Japanese Colleg
reserved.
ntroduction
nfusion of contrast media can lead to acute
enal insufﬁciency [1]. Contrast-induced nephropa-
hy (CIN) after percutaneous coronary intervention
PCI) is known to increase morbidity and mortal-
ty in patients with cardiovascular disease. Among
he baseline characteristics before contrast media
xposure, preexisting renal insufﬁciency, diabetic
ellitus, congestive heart failure, advanced age,
nd high-contrast volume exposure are reported to
e the risk factors related to CIN [1—3]. Although
he pathophysiological process of CIN is still contro-
ersial, a combination of renal circulation leading
omedullary ischemic damage, oxygen free radicals
nducing tubular cell alterations and parenchy-
al vasoconstriction are the main factors leading
o CIN [4]. Pre-procedural intravenous hydration,
-acetylcysteine, theophylline, and usage of lower-
smolar contrast media, as adjunctive treatments
uring angiographic procedures, are reported to
educe the incidence of CIN in patients with renal
nsufﬁciency [5,6].
The 3-hydroxy-3-methylglutaryl coenzyme A
eductase inhibitors (statins) became widely used
n patients with hypercholesterolemia, but statins
lso reduce the risk of cardiovascular disease,
rogression of nephropathy, and development of
iabetes because of their pleiotropic effects
ncluding improvement in endothelial dysfunction,
ncreased nitric oxide bioavailability, anti-oxidant
ffects, anti-inﬂammatory properties, and sta-
ilization of atherosclerotic plaques above and
eyond that of cholesterol lowering [7—10]. In addi-
ion, a recent report demonstrated that statins
revented CIN after PCI [11]. Although statins
re clinically expected as a new prophylactic
reatment, there are few reports regarding the
revention of CIN. From recent publications,
ravastatin (10mg/day), among several statins,
educed the rates of renal dysfunction in patients
ith cardiovascular disease and chronic kidney dis-
ase [12]. The aims of the present study were to
valuate whether chronic pravastatin treatment,
s a standard treatment of hypercholesterolemia,
<
r
u
n
hefore contrast media exposure, could reduce the
ncidence of CIN in patients with renal insufﬁ-
iency, and to elucidate the factors related to CIN
n patients receiving pre-procedural intravenous
ydration.
ethods
tudy patients
e evaluated 431 consecutive patients (367 men
nd 64 women, mean age 70.4± 8.9 years) with
enal insufﬁciency (deﬁned as serum creatinine
evel ≥1.1mg/dl) undergoing scheduled coronary
ngiography or PCI between April 2002 and October
008 at Kansai Medical University Hospital. The pre-
rocedure serum creatinine (baseline creatinine)
as measured before the contrast media exposure
nd peak post-procedure serum creatinine (maxi-
um creatinine) was measured within 48 h after
he exposure (immediately after, 24 h, 48 h). CIN
as deﬁned as an increase in the serum creati-
ine values of ≥0.5mg/dl or ≥25% increase within
8 h after the procedure in the absence of any
ther causes [13]. Creatinine clearance was cal-
ulated by applying the Cockcroft—Gault formula;
[140− age]× kg of body weight/(mgdl) of serum
reatinine× 72) with female gender adjustment
creatinine clearance× 0.85) [14]. The maximum
ose of contrast media that can be safely admin-
stered was calculated according to the following
ormula: 5ml/kg of body weight/(mgdl) of serum
reatinine (maximum, 300ml) [15]. All patients
ere hydrated with 1ml/(kg h) of half-isotonic
aline solution before and 12 h after the contrast
edia exposure and were monitored to avoid vol-
me overload.1.1mg/dl; (2) patients on chronic or tempo-
ary dialysis; (3) acute myocardial infarction or
nstable angina within 48 h; (4) emergency coro-
ary angiography that could not comply with our
ydration protocol; (5) congestive heart failure
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with low ejection fraction (<35%); (6) receiv-
ing other statin treatment. None of the patients
received noradrenalin, dopamine, theophylline, or
N-acetylcysteine in this study. Pravastatin was
administered for the treatment of hypercholes-
terolemia (serum cholesterol >200mg/dl) in 194
patients (45.0%). Pravastatin was started more than
at least 28 days before contrast media exposure.
Pravastatin dose was 10mg/day in 192 patients
and 20mg/day in 2 patients. We deﬁned diabetes
mellitus as receiving oral medication or insulin ther-
apy.
The patients were divided into CIN group and
non-CIN group; clinical variables and pre-procedure
medications were compared.
Coronary angiography and PCI
A non-ionic low-osmolality contrast media were
used in all patients. The patients were given at
least 3000 units of intravenous heparin and PCI was
performed by conventional techniques after intra-
venous administration of 10,000 units of heparin.
The target lesion (>75% stenosis) was successfully
dilated in all patients. The local ethical committee
on human research approved the study proto-
col and informed consent was obtained from all
patients.
Statistical analysis
The results are reported as the mean± standard
deviation. Statistical analysis between the 2 groups
was performed by the Student’s t test for contin-
uous variables and chi-square analysis or Fischer
exact test for discrete variables. All calculated p
values are 2-tailed. A p value <0.05 was considered
signiﬁcant. Logistic regression analysis using four
clinical variables (age, pre-procedure serum creati-
nine, contrast volume, and pravastatin treatment)
was performed to evaluate the important factors
related to CIN.
Results
Among 431 patients with scheduled coronary
angiography or PCI, the lesion was in the left ante-
rior descending coronary artery in 264 patients,
left circumﬂex coronary artery in 184 patients, and
right coronary artery in 210 patients. One hun-
dred ﬁfty-six patients had 1-vessel disease and
66 patients had 3-vessel disease. The mean pre-
procedure serum creatinine was 1.43± 0.34mg/dl
(range: 1.1—3.3mg/dl). Three patients in the
t
h
2
(
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on-CIN group had major complications during
oronary angiography or PCI. Coronary rupture
ccurred after ballooning in 1 patient, but was
mmediately managed by low-pressure balloon
xpansion. Cerebral infarction developed after
oronary angiography in 1 patient and right hemi-
legia lasted during hospitalization. Complete
eart block occurred during PCI using rotabla-
or in 1 patient and temporary pacemaker was
nserted.
omparisons of clinical characteristics
etween patients with and without
ravastatin
ne hundred ninety-four patients were taking
ravastatin (pravastatin) and 237 patients did
ot have statins (no pravastatin). Comparisons
f clinical characteristics between the 2 groups
re shown in Table 1. There were no signiﬁcant
ifferences between the 2 groups in lipid lev-
ls; hypercholesterolemia (pravastatin 26.8% vs.
o pravastatin 24.9%, p = 0.771), total choles-
erol (183.1± 37.5mg/dl vs. 181.9± 40.1mg/dl,
= 0.762), triglycerides (156.5± 88.4mg/dl vs.
41.6± 67.2mg/dl, p = 0.057) and low density
ipoprotein cholesterol (109.5± 37.7mg/dl vs.
08.9± 37.1mg/dl, p = 0.868). There were no
igniﬁcant differences between the 2 groups in
he incidence of diabetes mellitus (20.1% vs.
6.2%, p = 0.634), hemoglobin A1c (6.3± 1.3% vs.
.4± 2.1%, p = 0.543). Pre-procedure serum creati-
ine (pravastatin 1.4± 0.4mg/dl vs. no pravastatin
.4± 0.4mg/dl, p = 0.179), creatinine clear-
nce (41.4± 16.8ml/min vs. 39± 17.1ml/min,
= 0.157), administration of contrast volume
124.1± 53.8ml vs. 123.6± 51.4ml, p = 0.915)
nd incidence of patients exceeding maxi-
al allowable contrast dose (13.4% vs. 14.3%,
= 0.65) were identical between the 2 groups.
atients without pravastatin had a signiﬁ-
antly higher incidence of CIN (4.1% vs. 11.8%,
= 0.003).
ontrast-induced nephropathy
IN was observed in 36 patients (8.4%). Clinical
haracteristics and pre-procedure medications are
hown in Table 2. There were no signiﬁcant dif-
erences in advanced age, sex, hemoglobin A1c,
he incidence of diabetic mellitus, lipid disorder,
emoglobin, and body mass index between the
groups. Higher pre-procedure serum creatinine
lower creatinine clearance) and larger contrast
olume usage were observed in the CIN group
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Table 1 Comparison of clinical characteristics in patients with or without pravastatin.
Pravastatin treatment p-Value
(+) n = 194 (−) n = 237
Age (years) 69.9± 8.8 70.9± 8.9 0.233
Sex (male) 179 (92.3%) 188 (79.3%) 0.447
Pre-procedure serum creatinine (mg/dl) 1.4± 0.3 1.4± 0.3 0.179
Creatinine clearance (ml/min) 41.4± 16.8 39± 17.1 0.157
Diabetes mellitus (Hemoglobin A1c ≥6.5%) 39 (20.1%) 62 (26.2%) 0.634
Diabetes mellitus 48 (24.7%) 73 (30.8%) 0.602
Hemoglobin A1c (%) 6.3± 1.3 6.4± 2.1 0.543
Hypercholesterolemia (>200mg/dl) 52 (26.8%) 59 (24.9%) 0.771
Total cholesterol (mg/dl) 183.1± 37.5 181.9± 40.1 0.762
Triglycerides (mg/dl) 156.5± 88.4 141.6± 67.2 0.057
Low density lipoprotein cholesterol (mg/dl) 109.5± 37.7 108.9± 37.1 0.868
Hemoglobin (g/dl) 12.3± 2.0 12.1± 2.0 0.184
Body mass index (%) 24.2± 3.5 23.7± 3.7 0.199
Contrast volume (ml) 124.1± 53.8 123.6± 51.4 0.915
Exceeding maximal contrast dose 26 (13.4%) 34 (14.3%) 0.65
CIN 8 (4.1%) 28 (11.8%) 0.003
Clinical presentation
Previous myocardial infarction 110 (56.7%) 96 (40.5%) <0.001
Angina pectoris 47 (24.2%) 88 (37.1%) 0.004
Angiographic ﬁndings
Single vessel disease 58 (29.9%) 100 (42.2%) 0.008
Three vessel disease 29 (14.9%) 37 (15.6%) 0.849
Left anterior descending artery 123 (63.4%) 141 (60.8%) 0.407
Arteriosclerosis obliterans 6 (3.1%) 13 (5.5%) 0.249
Post-coronary bypass surgery 12 (6.2%) 21 (8.9%) 0.299
PCI 99 (51.0%) 106 (44.7%) 0.083
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CIN, contrast-induced nephropathy; PCI, percutaneous corona
ompared to the non-CIN group. The incidence of
xceeding the maximal allowable contrast dose was
ore frequently observed in patients with CIN.
mong the pre-proceduremedications, only pravas-
atin was more frequently given in the non-CIN
roup than in the CIN group and a signiﬁcantly
ower incidence of CIN was observed in patients
ith pravastatin compared to those without pravas-
atin (47.1% vs. 22.2%, p = 0.004) (Table 2). There
ere no signiﬁcant differences in clinical charac-
eristics and angiographic procedures between the
groups.
ogistic regression analysis
o determine the important variables related to
IN, logistic regression analysis using four variables
age, pre-procedure serum creatinine, contrast vol-
me, and pravastatin treatment) revealed that the
re-procedure serum creatinine, contrast volume
nd pravastatin treatment were the independent
ariables related to CIN (Table 3).
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w3.9± 13.2 53.9± 15.0 0.993
ervention.
iscussion
ontrast media used in diagnostic and interven-
ional angiographic procedures can cause acute
atrogenic renal insufﬁciency [1]. Furthermore,
eterioration of renal function within 48 h after
ontrast media exposure is implicated as a poor
rognosis in patients with preexisting renal insufﬁ-
iency [16]. The occurrence of CIN has signiﬁcant
hort- and long-term implications for patients’
utcome [2]. The number of angiographies using
ontrast media is increasing in clinical practice
nd higher doses are administered to sicker and
lder patients. Therefore, it is important to deter-
ine the factors related to CIN and to investigate
he pre-procedural treatments to prevent CIN. The
ncidence of CIN in a general population has been
alculated to be <2%, but the incidence of CIN has
een calculated to be 20—30% in high-risk patients:
atients with chronic renal insufﬁciency, diabetes
ellitus, congestive heart failure, and advanced
ge [1,13]. In this study, we investigated patients
ith mild renal insufﬁciency and found that the
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Table 2 Clinical characteristics and pre-procedure medication.
CIN p-Value
(−) n = 395 (+) n = 36
Age (years) 70.9± 8.9 72.9± 7.6 0.078
Sex (male) 339 (85.8%) 28 (77.8%) 0.341
Pre-procedure serum creatinine (mg/dl) 1.4± 0.3 1.6± 0.5 0.003
Creatinine clearance (ml/min) 40.9± 16.7 31.4± 18.3 0.001
Diabetes mellitus (Hemoglobin A1c ≥6.5%) 89 (22.5%) 12 (33.3%) 0.164
Diabetes mellitus 110 (27.8%) 11 (30.6%) 0.646
Hemoglobin A1c (%) 6.3± 1.8 6.4± 1.3 0.774
Hypercholesterolemia (>200mg/dl) 104 (26.3%) 7 (19.4%) 0.412
Total cholesterol (mg/dl) 182.9± 39.1 177.7± 36.7 0.447
Triglycerides (mg/dl) 147.4± 78.3 157.9± 71.2 0.465
Low density lipoprotein cholesterol (mg/dl) 108.7± 37.2 113.5± 38.2 0.483
Hemoglobin (g/dl) 12.3± 2.0 11.6± 2.3 0.093
Body mass index (%) 23.9± 3.39 24.1± 5.46 0.773
Contrast volume (ml) 122.2± 64.1 141.8± 64.0 0.034
Exceeding maximal contrast dose 46 (11.6%) 14 (38.9%) <0.001
Clinical presentation
Previous myocardial infarction 185 (46.8%) 21 (58.3%) 0.223
Angina pectoris 127 (32.2%) 8 (22.2%) 0.263
Three vessel disease 60 (15.2%) 6 (16.7%) 0.814
Left anterior descending artery 239 (60.5%) 25 (69.4%) 0.292
Left ventricular ejection fraction (%) 54.3± 13.6 49.5± 17.4 0.193
Pre-procedure medications
Angiotensin receptor blocker 159 (40.3%) 11 (30.6%) 0.254
Angiotensin-converting enzyme inhibitors 157 (39.7%) 17 (47.2%) 0.382
Pravastatin 186 (47.1%) 8 (22.2%) 0.004
Nicorandil 166 (42.0%) 18 (50%) 0.354
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pAspirin
Loop diuretic
CIN, contrast-induced nephropathy.
incidence of CIN was 8.4%. The incidence of CIN was
lower compared to other studies because we exam-
ined selected patients with stable hemodynamic
condition and our patients received pre-procedural
hydration with half-sonic solution to prevent CIN.
Presentation of CIN
Statins not only reduce the serum cholesterol lev-
els, but also protect renal function in patients with
advanced renal insufﬁciency and coronary artery
disease [12] by their pleiotropic effects including
anti-inﬂammatory and immunomodulatory [17,18],
t
w
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d
Table 3 Factors related to CIN.
Chi-square statistic
Age (years) 2.068
Pre-procedure Cr (mg/dl) 6.294
Pravastatin 6.549
Contrast volume (ml) 4.484
CIN, contrast-induced nephropathy; Cr, serum creatinine.7 (82.8%) 30 (83.3%) 0.933
1 (30.6%) 15 (41.7%) 0.178
ntithrombotic [19], and vascular effects [20].
hanal et al. reported that administration of statins
efore PCI was associated with a lower incidence
f CIN [11]. Although their ﬁndings suggested
hat statin therapy reduced the risk of CIN, the
esults remain tentative because of the hetero-
eneity of their patients with respect to inadequate
emodynamic states. Despite identical levels of
re-procedure serum creatinine and administra-
ion of contrast volume, we found that patients
ith pravastatin had signiﬁcantly lower incidence
f CIN compared to those without pravastatin. We
emonstrated pre-procedure chronic pravastatin
p-Value Odds ratio 95% CI
0.150 1.03 0.99—1.08
0.009 2.78 1.30—5.94
0.011 0.34 0.15—0.77
0.034 1.01 1.00—1.01
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Rrevention of contrast-induced nephropathy by pra
reatment used as a standard chronic treatment
f hypercholesterolemia was associated with the
eduction of CIN. In this study, the patients receiv-
ng pravastatin treatment were well controlled, and
here were no signiﬁcant differences between the
ravastatin group and the placebo group in the
erum lipid levels. Besides lipid lowering effects,
ur ﬁndings indicated that chronic pravastatin
reatment of hypercholesterolemia was important
n patients with cardiovascular disease. Although
he preventive mechanism of CIN by pravastatin
reatment remains unknown, it is mediated via
he pleiotropic actions rather than lipid lowering
ffects. Pravastatin (10mg/day) was effective in
educing proteinuria mediated by inhibiting renal
ndothelin-1 synthesis [21]. Moreover pravastatin
ay be more beneﬁcial for renal protection than
ther statins, because of its water-soluble struc-
ure. Standard doses (10—20mg/day) of pravastatin
ithout any adverse affect on organs (insulin secre-
ion from the pancreatic  cells, sugar uptake by
at cells or muscles) are reported to be effec-
ive in preventing coronary artery disease [22—25].
esirable the pleiotropic actions of water-soluble
tatins, pravastatin was beneﬁcial for the preven-
ion of CIN.
isk factors for CIN
lthough diabetes mellitus is one of the risk fac-
ors of CIN in patients with renal insufﬁciency [1],
here were no signiﬁcant differences in hemoglobin
1c level and history of diabetes mellitus between
he CIN and non-CIN groups in this study. There
s no deﬁnitive evidence that CIN correlates with
he duration of diabetes or suboptimal glycemic
ontrol, but adequate glycemic control should be
chieved before contrast media exposure in dia-
etic patients because acute hyperglycemia can
ead to direct renal damage [6,26]. Also, there is
o consensus regarding the role of advanced age as
risk factor of CIN [2,6]. In this study, age was not
predictive factor for CIN by the multivariate anal-
sis. A high prevalence of CIN in elderly patients is
ultifactorial in origin and may be attributable to
enal arteriosclerosis or panvasculopathy [6].
Pre-procedure intravenous hydration and low
ontrast volume exposure reduce CIN in patients
ith renal insufﬁciency [2,7]. According to these
eports, we performed routine pre-procedural
olume expansion and used contrast media at min-
mum dosage in all patients. However, there was a
igniﬁcantly higher incidence of patients exceed-
ng maximal contrast dose in the CIN group and
ontrast volume was found as an independent risk
actor related to CIN by the multivariate analysis.atin in patients with renal insufﬁciency 197
imitations of this study
hree limitations of this study should be addressed.
irst, there was no randomization of pravastatin
reatment in this study. However, signiﬁcant risk
actors for CIN such as contrast volume and pre-
rocedure serum creatinine were not different and
e excluded the potential effect of other unknown
onfounders as much as possible. Also, it was
ifﬁcult to evaluate whether chronic pravastatin
reatment could reduce the incidence of CIN by
andomization because it was predicted that there
re signiﬁcant differences between the 2 groups in
he serum lipid levels. Second, our observational
tudy was limited to a small sample size to elucidate
he effectiveness of pravastatin on development
f CIN in patients with severe renal insufﬁciency.
hird, the appropriate duration of pre-procedure
reatment and dosages of pravastatin to prevent
IN could not be clariﬁed. Nonetheless, we pro-
ide evidence that chronic pravastatin treatment
as an important prophylactic medication when
ssociated with a low dose of contrast media and
re-procedural hydration for patients with renal
nsufﬁciency.
onclusions
ravastatin treatment before contrast media expo-
ure was an important factor associated with the
eduction in CIN after coronary angiography or PCI
n patients with cardiovascular disease and renal
nsufﬁciency.
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